{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:08:03Z","timestamp":1751342883814,"version":"3.41.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","award":["200\u2009807","NCT02879305"],"award-info":[{"award-number":["200\u2009807","NCT02879305"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and hypothesis<\/jats:title>\n                  <jats:p>Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients). In PD patients, prespecified analyses of the co-primary endpoints of mean change in hemoglobin from baseline to Weeks 28\u201352 using an ANOVA model and first occurrence of a major cardiovascular event (MACE) using a Cox proportional hazards model were conducted. The secondary endpoints were average monthly intravenous iron dose to Week 52 and treatment-emergent adverse events. Additional post hoc analyses were conducted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 340 PD patients (daprodustat n\u00a0=\u00a0171, darbepoetin alfa n\u00a0=\u00a0169) were randomized. Mean age was 53.6 years (\u00b114 SD), 55% male, 56% White. For daprodustat and darbepoetin alfa groups respectively, mean change in hemoglobin was 0.38 and 0.23\u00a0g\/dL [adjusted mean difference 0.15, 95% confidence interval (CI), \u22120.04, 0.34], and first occurrence of adjudicated MACE occurred in 40 (23.4%) and 46 (27.2%) patients (HR 0.84; 95% CI, 0.55\u20131.28). No heterogeneity was observed between PD and HD patients for these endpoints in ASCEND-D. Serum hepcidin was lower with daprodustat; there was no difference in other iron parameters, intravenous iron usage, transfusion requirement, blood pressure, or quality of life. There were no differences in adverse events or incidence of peritonitis between the groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This subgroup analysis of the ASCEND-D trial demonstrated comparable efficacy and safety of daprodustat versus darbepoetin alfa in PD patients, supporting its use in the treatment of anemia in these patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfae273","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T10:37:03Z","timestamp":1737023823000},"page":"1332-1341","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of daprodustat in patients on peritoneal dialysis in the ASCEND-D trial"],"prefix":"10.1093","volume":"40","author":[{"given":"Indranil","family":"Dasgupta","sequence":"first","affiliation":[{"name":"University Hospitals of Birmingham NHS Foundation Trust Department of Renal Medicine, , Birmingham ,","place":["UK"]},{"name":"University of Warwick Warwick Medical School, , Coventry ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy M","family":"Meadowcroft","sequence":"additional","affiliation":[{"name":"GSK Clinical Sciences (Renal Disease) Development, Pharma R&D, , Collegeville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purav R","family":"Bhatt","sequence":"additional","affiliation":[{"name":"GSK Clinical Sciences (Renal Disease) Development, Pharma R&D, , Collegeville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Acharya","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine Department of Medicine (Nephrology), Jacobi Medical Center, , New York City, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Aarup","sequence":"additional","affiliation":[{"name":"Odense University Hospital Department of Nephrology, , Odense ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Correa-Rotter","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n Department of Medicine and Nephrology, , Mexico City ,","place":["Mexico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-2151","authenticated-orcid":false,"given":"Shruti","family":"Gupta","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital Division of Nephrology, , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay K","family":"Kher","sequence":"additional","affiliation":[{"name":"Medanta Hospital Department of Nephrology, Medanta Kidney and Urology Institute, , South Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osvaldo M Viera","family":"Neto","sequence":"additional","affiliation":[{"name":"Sociedade Brasileira de Nefrologia Department of Nephrology, , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjay","family":"Rastogi","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine UCLA Division of Nephrology, , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Ots-Rosenberg","sequence":"additional","affiliation":[{"name":"Tartu University and Tartu University Hospital Nephrology Division, , Tartu ,","place":["Estonia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Rayner","sequence":"additional","affiliation":[{"name":"Groote Schuur Hospital and University of Cape Town Division of Nephrology and Hypertension, , Cape Town ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muh Geot","family":"Wong","sequence":"additional","affiliation":[{"name":"University of Sydney Faculty of Medicine, , Sydney ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunay","family":"Shah","sequence":"additional","affiliation":[{"name":"GSK Clinical Sciences (Renal Disease) Development, Pharma R&D, , Collegeville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Taft","sequence":"additional","affiliation":[{"name":"GSK Clinical Sciences (Renal Disease) Development, Pharma R&D, , Collegeville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K","family":"Singh","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n Department of Medicine and Nephrology, , Mexico City ,","place":["Mexico"]},{"name":"Harvard Medical School Postgraduate Medical Education, , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"2025063007561560600_bib1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-016-0312-9","article-title":"Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia","volume":"17","author":"Eriksson","year":"2016","journal-title":"BMC Nephrol"},{"key":"2025063007561560600_bib2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","article-title":"Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data","volume":"21","author":"van Haalen","year":"2020","journal-title":"BMC Nephrol"},{"key":"2025063007561560600_bib3","first-page":"279","article-title":"Clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"KDIGO","year":"2013","journal-title":"Kidney Int Suppl (2013)"},{"key":"2025063007561560600_bib4","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2025063007561560600_bib5","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"2025063007561560600_bib6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","article-title":"Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial","volume":"182","author":"Singh","year":"2022","journal-title":"JAMA Intern Med"},{"author":"US FDA","key":"2025063007561560600_bib7","article-title":"FDA approves first oral treatment for anemia caused by chronic kidney disease for adults on dialysis"},{"key":"2025063007561560600_bib8","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40265-020-01384-y","article-title":"Daprodustat: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"2025063007561560600_bib9","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.kint.2023.02.019","article-title":"The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease","volume":"103","author":"Johansen","year":"2023","journal-title":"Kidney Int"},{"key":"2025063007561560600_bib10","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad063a_4140","article-title":"#4140 Daprodustat versus recombinant human erythropoietin for treating anaemia of chronic kidney disease: cost effectiveness model methodology and findings","volume":"38","author":"Sackeyfio","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025063007561560600_bib11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/ndt\/gfab065","article-title":"Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial","volume":"37","author":"Singh","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2025063007561560600_bib12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2025063007561560600_bib13","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5\u00a0L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"2025063007561560600_bib14","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"2025063007561560600_bib15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s40001-023-01465-0","article-title":"Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study","volume":"28","author":"Zhang","year":"2023","journal-title":"Eur J Med Res"},{"key":"2025063007561560600_bib16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","article-title":"Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial","volume":"121","author":"Hou","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"2025063007561560600_bib17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"2025063007561560600_bib18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1053\/j.jrn.2021.09.003","article-title":"A prospective, self-controlled pilot study of the efficacy of roxadustat for erythropoietin hyporesponsiveness in patients requiring chronic ambulatory peritoneal dialysis","volume":"32","author":"Chen","year":"2022","journal-title":"J Ren Nutr"},{"key":"2025063007561560600_bib19","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/1744-9987.13713","article-title":"Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study","volume":"26","author":"Akizawa","year":"2022","journal-title":"Ther Apher Dial"},{"key":"2025063007561560600_bib20","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1093\/ndt\/gfad074","article-title":"Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis","volume":"38","author":"Sarnak","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025063007561560600_bib21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1159\/000518073","article-title":"HIF-prolyl hydroxylase inhibitors: confirmed efficacy with uncertain safety","volume":"52","author":"Roger","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025063007561560600_bib22","first-page":"641","article-title":"Preferences for anaemia treatment attributes among patients with non-dialysis-dependent chronic kidney disease","author":"Alexandre","year":"2023"},{"key":"2025063007561560600_bib23","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non\u2013dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"2025063007561560600_bib24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1159\/000518072","article-title":"Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study","volume":"52","author":"Yamamoto","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025063007561560600_bib25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1159\/000518071","article-title":"Efficacy and safety of molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial","volume":"52","author":"Yamamoto","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025063007561560600_bib26","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1038\/ki.2008.524","article-title":"Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study","volume":"74","author":"Portol\u00e9s","year":"2008","journal-title":"Kidney Int"},{"key":"2025063007561560600_bib27","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.2215\/CJN.04920908","article-title":"Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality","volume":"4","author":"Boudville","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025063007561560600_bib28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int Suppl"},{"key":"2025063007561560600_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MAJ.0b013e318253caf1","article-title":"Hepcidin and iron regulation in health and disease","volume":"345","author":"Means","year":"2013","journal-title":"Am J Med Sci"},{"key":"2025063007561560600_bib30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cmet.2020.08.002","article-title":"The role of HIF in immunity and inflammation","volume":"32","author":"McGettrick","year":"2020","journal-title":"Cell Metab"},{"key":"2025063007561560600_bib31","doi-asserted-by":"publisher","first-page":"967532","DOI":"10.3389\/fphar.2022.967532","article-title":"Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis","volume":"13","author":"Chong","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025063007561560600_bib32","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s13063-021-05574-1","article-title":"Standardised Outcomes in Nephrology\u2014Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy","volume":"22","author":"Evangelidis","year":"2021","journal-title":"Trials"},{"key":"2025063007561560600_bib33","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.kint.2018.08.018","article-title":"Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop","volume":"94","author":"Tong","year":"2018","journal-title":"Kidney Int"},{"key":"2025063007561560600_bib34","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/ckj\/sfab070","article-title":"Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney","volume":"14","author":"Vanholder","year":"2021","journal-title":"Clin Kidney J"},{"key":"2025063007561560600_bib35","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume-title":"N Engl J Med","author":"Besarab","year":"1998"},{"key":"2025063007561560600_bib36","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume-title":"N Engl J Med","author":"Dr\u00fceke","year":"2006"},{"key":"2025063007561560600_bib37","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume-title":"N Engl J Med","author":"Singh","year":"2006"},{"key":"2025063007561560600_bib38","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2025063007561560600_bib39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12955-018-0933-8","article-title":"Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy\u2014Anemia (FACT-An) in patients with anemia associated with chronic kidney disease","volume":"16","author":"Finkelstein","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"2025063007561560600_bib40","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/ndt\/18.2.362","article-title":"Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)","volume":"18","author":"Locatelli","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2025063007561560600_bib41","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41581-020-0315-4","article-title":"The current and future landscape of dialysis","volume":"16","author":"Himmelfarb","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025063007561560600_bib42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrneph.2016.181","article-title":"Changes in the worldwide epidemiology of peritoneal dialysis","volume":"13","author":"Li","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2025063007561560600_bib43","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.09.119","article-title":"Are we approaching a new era in the treatment of anemia of chronic kidney disease patients?","volume":"7","author":"Locatelli","year":"2019","journal-title":"Ann Transl Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae273\/60781463\/gfae273.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/7\/1332\/60781463\/gfae273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/7\/1332\/60781463\/gfae273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T11:56:24Z","timestamp":1751284584000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/7\/1332\/7906608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,11,21]]},"published-print":{"date-parts":[[2025,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae273","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"type":"print","value":"0931-0509"},{"type":"electronic","value":"1460-2385"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2024,11,21]]}}}